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with constipation and 1:1 matched controls without constipa-
tion. Two- part semi-logarithmic multivariate regression models
were estimated to assess the impact of constipation on all-cause
resource utilization and costs. Smearing estimates were applied
to interpret results of the semi-logarithmic models. RESULTS:
We identiﬁed 39,485 patients of whom 2,519 (6.4%) had con-
stipation. Most patients with constipation were female (66%)
and 45 years old (68%). Compared to controls, the constipa-
tion group had higher rates of concurrent use of 2 opioids
(36% vs 24%; p < 0.001), discontinuation (31% vs 25%;
p < 0.001), and switching (45% vs 28%; p < 0.001) between
opioids. Patients with constipation were more likely to have
inpatient admission (odds ratio [OR] = 2.13; p < 0.001), emer-
gency (OR = 2.25; p < 0.001), outpatient visits (OR = 9.45;
p < 0.001), skilled nursing (OR = 2.26; p < 0.001), hospice
(OR = 2.27; p < 0.001) and home health services (OR = 1.54;
p < 0.001). Patients with constipation had signiﬁcantly higher
all-cause costs for emergency ($1,277 vs. $588), outpatient
($3,635 vs $1,861), nursing facility ($1,885 vs. $613), home
health ($1,909 vs. $1,069) and prescription drug ($12,005 vs
$6,809) services compared to patients without constipation.
CONCLUSION: Presence of constipation in opioid-treated
patients was found to have signiﬁcant impact on opioid use
patterns, health care utilization, and associated costs.
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OBJECTIVES: To estimate the economic burden of Digital
Ulcers (DU) in patients affected by Systemic Sclerosis (SSc, scle-
roderma), in the perspective of the NHS, patients, and society.
METHODS: Pilot, observational study based on a retrospective,
one-year, data collection of clinical characteristics and consump-
tion of resources in the target population, at the Rheumatology
Unit of the University Hospital in Padova. EC approval and
informed consent were obtained. Clinical records of adults with
limited/diffuse SSc, who developed >1 new DU (from September
2005 to April 2006) were analysed. Direct cost and indirect cost
per patient/year were calculated using 2007 published tariffs and
market values. RESULTS: Twenty patients (90% females) (age
51 +/- 12 yr), 60% affected by limited SSc and 80% by severe
DU (average nDU = 3) were included. Twenty percent of patients
had longer SSc history and more severe DU. All patients received
home treatments; 55% also received outpatient care; 85%
received on average 3.7 cycles of prostanoids (iloprost or alpros-
tadil) in the DH setting, 15% were also hospitalised. DU com-
plications, mostly superinfections, occurred in 85% of patients.
80% of patients healed. In the NHS perspective, cost of DU is on
average €23,730 per patient/year, 71.8% due to DH treatments
(including prostanoids) and 23.7% to management of complica-
tions; cost per patient varies from €20,533 (no complications,
average nDU = 1) to €24,295 (with complications, average
nDU = 4); main cost driver is the number of DH accesses. Out-
of-pocket expenditure is lower for patients with complications
(€360 vs. €900/year) as cost of complications is mainly borne by
the NHS. Cost/patient/year is on average €26,756 in the societal
perspective (€27,309 and €23,619 with/without complications);
indirect costs increase when complications occur. CONCLU-
SION: Despite the small sample, DU economic burden is relevant
because of DH treatments and complications’ management. In
absence of complications, cost of management shifts to patients’
charge.
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OBJECTIVES: Crohn’s disease (CD) is a potentially expensive
disease as it is a chronic, not curable condition with high hospi-
talisation rates. The objective of the study was to estimate the
health care resource use and epidemiology in a large UK popu-
lation. METHODS: This was a retrospective study using NHS
inpatient data (HES data) from 2001 over a period of 5 years
representing England (population in 2001 49,140,000). To
compare these results data from the region of Cardiff, Wales, UK
(population in 2003 approximately 434,000) was used. This data
contains inpatient, outpatient, biochemistry and mortality data
over a period of at least 12 years that has undergone record
linkage. Patients included were those with a diagnosis of CD
(ICD-10 K50*) as cause of admission. Number, type and method
of admission, incidence and survival were analysed. HRGs were
used to calculate inpatient costs. RESULTS: A total of 18,573
patients were identiﬁed in the NHS data [644 Cardiff data], of
whom 7,666 (41.3%) [250 (38.8%) Cardiff data] were male. The
average incidence was 14 per 100,000 per year. Mean length of
stay for primary index admissions was 9.2 (SD 14.7) days and
mean costs 2304 (SD 2778). Re-admission rates (primary or
secondary ICD code) in the year after index admission were 1.36
(SD 3.26) and disease related 0.83 (SD 2.34) per patient; average
length of stay per admission were 6.5 (SD 14.6), average costs
1776 (SD 2692). Surgery rate in the year after index admis-
sion was 0.16 (SD 0.46); average length of stay 12.5 (SD 22.1),
average costs per surgery 4048 (SD 4158). The rates declined
over the follow-up years. Hospital days, costs and rates approxi-
mately matched the Cardiff data, but were slightly higher. CON-
CLUSION: This study provides epidemiological and resource use
information on patients with CD. It conﬁrms the high resource
use and gives insight into determinants.
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OBJECTIVES: Ulcerative colitis (UC) is a potentially expensive
disease since it is a chronic condition with high hospitalisation
rates. The objective of the study was to estimate the health
care resource use and epidemiology in a large UK population.
METHODS: This was a retrospective study using NHS inpatient
data (HES data) from 2001 over a period of 5 years representing
England (population in 2001 49,140,000). To compare these
results data from the region of Cardiff, Wales, UK (population in
2003 approximately 434,000) was used. This data contains inpa-
tient, outpatient, biochemistry and mortality data over a period
of at least 12 years that has undergone record linkage. Patients
included were those with a diagnosis of UC (ICD-10 K51*) as
cause of admission. Number, type and method of admission,
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incidence and survival were analysed. HRGs were used to cal-
culate inpatient costs. RESULTS: A total of 22,657 patients
were identiﬁed in the NHS data [592 Cardiff data], of whom
11,719 (51.2%) [288 (48.6%) Cardiff data] were male. The
average incidence was 13 per 100,000 per year. Mean length of
stay for primary index admissions was 11.3 (SD 15.4) days and
mean costs 2524 (SD 2757). Re-admission rates (primary
or secondary ICD code) in the year after index admission were
0.88 (SD 2.42) and disease related 0.32 (SD 0.99) per patient;
average length of stay per admission were 9.9 (SD 18.4),
average costs 2441 (SD 3244). Surgery rate in the year after
index admission was 0.10 (SD 0.38); average length of stay
13.5 (SD 21.2), average costs per surgery 4175 (SD 3175).
The rates declined over the follow-up years. Costs and rates
approximately matched the Cardiff data, hospital days were
slightly lower. CONCLUSION: This study provides epidemio-
logical and resource use information on patients with Ulcer-
ative colitis. It conﬁrms the high resource use and gives insight
into the determinants.
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OBJECTIVES: To evaluate the impact of persistence with
inﬂiximab treatment on medical costs among patients with
Crohn’s disease (CD), using a managed care database.
METHODS: A retrospective study using the PharMetrics
managed care plan database in the US from July 1, 1999
through June 30, 2005 was conducted. Patients newly initiated
on inﬂiximab, continuously enrolled for 12 months before and
after their index inﬂiximab claim, and having at least two diag-
noses of CD (one of which occurring in the pre-index period)
were included. Persistence (%) was deﬁned as the number of
days between the ﬁrst inﬂiximab claim and the last inﬂiximab
encounter, divided by 365 and multiplied by 100. Two mutu-
ally exclusive cohorts were deﬁned based on the levels of inﬂix-
imab persistence: patients who were persistent >=80% and
those who were persistent <80%. CD-related medical costs
(those in which CD was the diagnosis) in the 12-month
post-index period were computed for each patient. The cost
of adverse events could not be identiﬁed separately in this
analysis. Univariate differences between the persistent and
non-persistent cohorts were assessed using Mann-Whitney and
chi-square tests. RESULTS: Four hundred, eighty patients were
included, 251 (52.29%) with a persistency ratio >=80% and
229 (47.71%) with a persistency ratio <80%; 55% were female
and the mean age was 36.9 years. The 80% persistency cohort
had lower CD-related medical costs compared with the <80%
persistency cohort ($4380.21 versus $8570.11; p = ns), prima-
rily driven by inpatient costs ($2014.31 versus $5981.51;
p < 0.001). Costs were also higher for emergency room and
outpatient levels of care in the lower persistency cohort. CON-
CLUSION: This study indicates that a higher persistence rate
with inﬂiximab therapy is associated with lower CD-related
medical costs, primarily driven by decreased inpatient hospital
costs. Future studies to examine the impact of persistence
with inﬂiximab on clinical and humanistic outcomes are
recommended.
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OBJECTIVES: Evaluate health care utilization/costs associated
with pediatric Crohn’s disease (PCD). METHODS: Claims for
HMO patients assigned to HealthCare Partners Medical Group
from six commercial health plans in Southern California were
analyzed, which identiﬁed patients <18 who were newly diag-
nosed with PCD (ICD-9 555.x) for this analysis. Patients were
required to have 6-months pre and 12-months post continuous
eligibility from disease index date. Cost and resource utilization
were compared to a cohort of non-PCD claimants, matched to
the PCD cohort on age, sex, and birthday (within 30 days of
age/sex matched PCD patients). Statistical signiﬁcance was not
assessed due to small sample size. RESULTS: Sixty-two PCD
patients were identiﬁed; 30 met the eligibility criteria; 56.7%
were female and median age at diagnosis was 13. The compara-
tor group included 10,864 children. The total per member per
month (PMPM) cost for PCD patients was $2547.32 (70%
attributable to PCD), as compared with $166.07 PMPM for the
non-PCD cohort. There were 500 admissions per thousand
members per year (PTMPY) for the PCD group as compared
with 11.2 for the comparator cohort. The average length of stay
was 7.6 days for the PCD cohort versus 4.4 days for the com-
parators. Inpatient stay PMPM cost was $1409.41 for the PCD
cohort versus $18.16 for the comparators. CONCLUSION: PCD
is associated with much higher levels of resource utilization and
costs of care, primarily driven by inpatient stays, compared with
a matched group of children without PCD. Treating PCD appro-
priately before the disease progresses to a level requiring hospi-
talization may help reduce costs.
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OBJECTIVES: Examine inpatient hospital utilization, following
colectomy, in patients with ulcerative colitis (UC) covered by
Medicare. METHODS: A retrospective analysis was conducted
using claims from the Medicare Standard Analytic Files (SAF)
5% sample database between January 1, 2001 and December 31,
2005. Patients with UC were identiﬁed using diagnostic codes
(ICD-9 codes 556.x) and were limited to those with a procedure
code indicating colectomy (45.7x), and a diagnosis of UC prior
to that date. Patients with a subsequent diagnosis of Crohn’s
disease were eliminated from this analysis. The ﬁrst procedure
was chosen if the beneﬁciary had multiple 45.7x procedures
(these are partial excisions, so a beneﬁciary could have multiple
procedures over time). The study design consisted of a 12-month
pre- and 12-month post-colectomy period during which con-
tinuous enrollment was required. Inpatient hospital costs
and resource utilization were evaluated 12-months before and
12-months after the quarter in which the colectomy occurred. All
costs are presented in 2005 US dollars. RESULTS: A total of 905
patients with UC who had a claim for colectomy were included
in the analysis. Total inpatient costs ($19,778 vs. $23,765) and
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